Pediatrics (System-Integrated)

Otitis media with effusion: management and referral

Clinical Overview and When to Suspect Otitis Media with Effusion

— Affects ~90% of children at least once before school age, peak 6 months to 4 years

— Most episodes follow an acute otitis media (AOM) or viral URI; ~60–70% resolve within 3 months

— Bimodal age peaks: 2 years (daycare exposure) and 5 years (school entry)

— Eustachian tube dysfunction → negative middle ear pressure → transudate/sterile effusion

— Biofilms and low-grade inflammation maintain fluid; not actively infected but not "normal"

— Adenoid hypertrophy contributes via mechanical obstruction and bacterial reservoir

— Child brought in for "failed school hearing screen," speech delay, or inattention

— Parent notes child turning TV volume up, mishearing, balance complaints

— Recent AOM treated 4–6 weeks ago, now asymptomatic but TM still abnormal

— Incidental finding on well-child exam with dull, retracted, or amber TM

— Daycare attendance, passive smoke exposure, bottle propping, pacifier use beyond 12 months

— Allergic rhinitis, GERD, craniofacial anomalies (cleft palate, Down syndrome)

— Absence of breastfeeding, low socioeconomic status

— Most common cause of acquired hearing loss in children and a frequent reason for outpatient referral

— Decisions hinge on duration, laterality, hearing impact, and developmental risk — not antibiotics

Board pearl: OME = fluid + no acute inflammation. If the stem mentions fever, ear pain, or a bulging red TM, you are looking at AOM, not OME. The Step 3 trap is reflexively prescribing amoxicillin for any middle ear fluid — OME does not warrant antibiotics, decongestants, antihistamines, or intranasal steroids as routine therapy.

Definition: Otitis media with effusion (OME) is middle ear fluid without signs of acute infection — no bulging erythematous TM, no fever, no otalgia of acute onset

Epidemiology:

Pathophysiology:

When to suspect OME on Step 3 vignettes:

Risk factors flagged in stems:

Why it matters for Step 3:

Presentation Patterns and Key History

— Many children have no complaints; OME is detected on routine exam or screening

— Step 3 stems often frame it as "post-AOM follow-up at 4 weeks" with persistent effusion

— Conductive hearing loss: "Doesn't respond when called," "turns TV up," school inattention

— Speech and language delay: Reduced expressive vocabulary, articulation errors, especially if bilateral and persistent

— Balance disturbance: Clumsiness, delayed gross motor milestones (vestibular fluid effect)

— Aural fullness or popping in older verbal children; rarely true pain

— Sleep disturbance or behavioral changes (irritability, frustration)

— Duration of suspected effusion — the 3-month threshold drives management

— Laterality — unilateral vs bilateral (bilateral has greater developmental impact)

— Prior AOM episodes, prior tympanostomy tubes, recent URI

— Hearing concerns from parents/teachers; results of any school screening

— Speech/language milestones — using age-appropriate benchmarks

— Daycare attendance, household smoking, breastfeeding history

— Persistent unilateral effusion in an adult or adolescent → evaluate for nasopharyngeal mass (carcinoma in adults, especially Southern Chinese, EBV-related)

— Craniofacial syndromes (cleft palate, Down, Turner) — higher persistence rate, lower spontaneous resolution

— Concurrent vision impairment, developmental delay, autism — "at-risk child" designation changes thresholds

— Parent's perception of hearing is moderately sensitive but not sufficient — formal audiometry still required

— Assess school performance, IEP status, prior speech therapy

Key distinction: AOM = acute onset of pain/fever + bulging TM. OME = fluid + no acute symptoms. Chronic OME = ≥3 months. The duration determines whether you watch, refer for audiology, or refer for tubes — memorize this axis.

Classic asymptomatic presentation:

Symptomatic presentations to recognize:

Critical history elements (Step 3 checklist):

Red-flag history requiring urgent attention:

Family-centered history:

Physical Exam Findings and Otoscopic Assessment

— Required skill on Step 3 management questions; mere static otoscopy is insufficient

— Dull, opaque, or amber-yellow TM (vs pearly gray normal)

— Air-fluid levels or visible bubbles behind the TM — pathognomonic when present

— Retracted TM with prominent lateral process of malleus, foreshortened malleus handle

— Loss of light reflex; TM may appear bluish (vs hemotympanum which is darker)

— No bulging, no erythema, no purulence — distinguishes from AOM

— Proper seal with appropriately sized speculum

— Apply gentle positive then negative pressure with the bulb

— Reduced or absent TM mobility = effusion or high negative middle ear pressure

— Hypermobile TM suggests tympanosclerosis or perforation healing, not OME

— Inspect nasopharynx for adenoid facies, mouth breathing, hyponasal speech

— Evaluate for allergic shiners, transverse nasal crease, cobblestoning of posterior pharynx

— Cleft palate exam — including submucous cleft (bifid uvula, notched hard palate, zona pellucida)

— Tonsillar size and Mallampati for surgical planning

— Cervical lymphadenopathy

— Whispered voice test, finger-rub — gross only

— Formal audiometry and tympanometry are needed for documentation

— Always perform nasopharyngoscopy or imaging for unilateral adult OME — rule out nasopharyngeal carcinoma, especially with neck mass or cranial nerve findings

Step 3 management: If pneumatic otoscopy is uncertain, tympanometry is the next confirmatory step before committing to a watch-and-wait vs referral pathway. Do not order CT or MRI routinely for pediatric OME — imaging is reserved for suspected mass or complication.

Pneumatic otoscopy is the diagnostic gold standard for OME — AAO-HNS strongly recommends it

Tympanic membrane findings:

Pneumatic otoscopy technique:

Additional examination:

Audiologic bedside maneuvers (limited utility in young children):

Adult-specific exam:

Diagnostic Workup — Tympanometry, Audiometry, and Initial Studies

— Measures TM compliance across a pressure gradient

— Type A: normal peak around 0 daPa — rules out effusion

— Type B (flat tracing): no peak, low compliance → effusion or perforation/tube (check ear canal volume)

— Normal canal volume + flat = effusion (classic OME)

— Large canal volume + flat = patent tube or perforation

— Type C: peak shifted to negative pressure (<−150 daPa) = eustachian tube dysfunction, may precede or follow OME

— Age-appropriate testing:

— <6 months: otoacoustic emissions (OAE), auditory brainstem response (ABR)

— 6 months to 2.5 years: visual reinforcement audiometry (VRA)

— 2.5 to 4 years: conditioned play audiometry

— ≥4 years: conventional pure-tone audiometry

— Expected pattern: mild conductive hearing loss (~25–30 dB), occasionally up to 40 dB

— Air-bone gap confirms conductive component

— Document baseline before any surgical intervention

— Refer if bilateral OME ≥3 months with hearing loss ≥20 dB or any speech/language concern

— Mandatory in "at-risk" children regardless of duration

— No imaging (CT/MRI) unless mass, complication (mastoiditis, intracranial extension), or unilateral adult OME

— No allergy testing as routine first step

— No serologic workup; OME is a clinical-plus-tympanometric diagnosis

— Date of onset, laterality, audiometric results, developmental status — needed before ENT referral and tubes

Board pearl: A Type B tympanogram with normal ear canal volume is the classic OME confirmation. If canal volume is high (>1.0 mL pediatric, >2.0 mL adult) with flat tracing, suspect patent tube or TM perforation, not active OME.

Tympanometry — workhorse confirmatory test:

Audiometry — required for chronic OME (≥3 months) or any hearing concern:

Speech and language evaluation:

Tests NOT routinely indicated:

Documentation requirements:

Diagnostic Workup — Identifying At-Risk Children and Confirmatory Considerations

— Permanent hearing loss independent of OME

— Suspected or confirmed speech/language delay or disorder

— Autism spectrum disorder, other pervasive developmental disorders

— Syndromes (Down, craniofacial) or disorders affecting cognitive, speech, language development

— Blindness or uncorrectable visual impairment

— Cleft palate with or without other syndromes

— Developmental delay

— Do not apply the standard 3-month watchful waiting window passively

— Earlier audiology, earlier ENT referral, earlier consideration of tympanostomy tubes

— Closer monitoring intervals (every 3 months rather than 6)

— Acoustic reflectometry — portable, useful in primary care; reasonable alternative when tympanometry unavailable

— Tympanocentesis — diagnostic and therapeutic; rarely needed in routine OME, reserved for immunocompromised or atypical cases

— In adults: flexible nasopharyngoscopy is mandatory — rule out nasopharyngeal carcinoma; consider MRI with contrast if exam suspicious

— In children: persistent unilateral OME warrants ENT referral but malignancy concern is much lower; still evaluate for nasopharyngeal mass if other findings (epistaxis, neck mass, cranial neuropathy)

— Consider in children with chronic/recurrent OME plus allergic rhinitis features

— Treating underlying allergic rhinitis may help but is not first-line OME therapy

— Consider in recurrent OME with other infections (sinopulmonary, skin) — quantitative immunoglobulins, response to vaccines

Key distinction: Adult with new unilateral middle ear effusion = nasopharyngeal carcinoma until proven otherwise. This is a recurring Step 3 trap — the answer is nasopharyngoscopy, not antibiotics or observation. EBV-associated NPC classically presents this way.

"At-risk child" designation (AAO-HNS) — lowers thresholds for intervention:

Implications of at-risk status:

Confirmatory adjuncts:

Unilateral OME workup considerations:

Allergy and reflux evaluation:

Immunologic workup:

Risk Stratification and First-Line Management Logic

— <3 months duration, non-at-risk child: watchful waiting with reassessment every 3 months

— Spontaneous resolution rate: ~75–90% by 3 months when OME follows AOM

— Document onset date carefully — Step 3 stems will hide this in the timeline

— Reassess at 3-month intervals with pneumatic otoscopy and/or tympanometry

— Educate family about hearing impact, signs of worsening

— Optimize modifiable risk factors: eliminate tobacco smoke exposure, address daycare contacts, encourage breastfeeding under age 1

— Persistent bilateral OME ≥3 months with documented hearing loss

— At-risk child with OME of any duration

— Structural TM/middle ear damage suspected: retraction pocket, ossicular erosion, cholesteatoma concern

— Recurrent AOM (≥3 in 6 months or ≥4 in 12 months) with effusion between episodes

— Antibiotics — no role in uncomplicated OME

— Antihistamines and decongestants — ineffective and may cause harm in children

— Intranasal or systemic steroids — short-term benefit at best, not recommended for routine use

— Mucolytics, homeopathy

— Autoinflation (balloon devices) — modest benefit in older cooperative children; reasonable adjunct

— Treatment of comorbid allergic rhinitis if present, on its own merits

— Audiometry at 3-month mark in persistent cases

— Formal speech-language evaluation when bilateral hearing loss ≥20 dB or developmental concern

Step 3 management: The single highest-yield decision tree: bilateral OME persisting ≥3 months + hearing loss ≥21 dB in the better ear → refer for tympanostomy tubes. Memorize this trigger; it determines the right answer on most OME vignettes.

The 3-month rule anchors decision-making:

Watchful waiting protocol:

Indications to escalate from watch-and-wait:

Therapies NOT recommended (AAO-HNS strong recommendations against):

Therapies with limited/optional role:

Hearing/speech surveillance:

Pharmacotherapy — What Not to Prescribe and Limited Adjuncts

— AAO-HNS, AAP, and AAFP all strongly recommend against routine antibiotics

— Antibiotics offer transient effusion clearance with high relapse, plus resistance and side effects

— Step 3 distractors will offer amoxicillin, amoxicillin-clavulanate, azithromycin — these are wrong for uncomplicated OME

— Strong recommendation against in children with OME

— No effect on effusion clearance; in children <6 years, antihistamines and decongestants carry meaningful adverse effects (sedation, paradoxical agitation, anticholinergic toxicity, cardiovascular events)

— FDA warns against OTC cough/cold combination products in children <4 years

— Not recommended as routine OME therapy

— Reasonable only if comorbid allergic rhinitis is independently diagnosed and being treated

— Modest short-term effusion benefit in trials, not durable

— Not recommended; risk-benefit unfavorable for a generally self-limited condition

— Optional adjunct in children ≥3–4 years who can cooperate

— Modest short-term benefit on effusion and tympanogram normalization

— Low risk, low cost — reasonable to offer while awaiting resolution

— Allergic rhinitis: intranasal steroids, second-generation antihistamines on their own merits

— GERD: lifestyle measures; PPIs only if reflux independently established

— Tobacco smoke elimination — strongly counsel; among the most evidence-based interventions

— Pneumococcal conjugate (PCV15/20) and influenza vaccines reduce AOM incidence and indirectly OME burden

Board pearl: If a Step 3 question offers "amoxicillin, oral prednisone, oral pseudoephedrine, or refer to audiology for child with 3-month bilateral effusion" — the answer is audiology referral. Pharmacotherapy is a trap; OME is managed by surveillance and surgery, not pills.

Core principle: OME is NOT an antibiotic-responsive condition

Antihistamines and decongestants:

Intranasal corticosteroids:

Systemic corticosteroids:

Autoinflation devices (e.g., Otovent balloon):

Treating contributors:

Vaccination optimization:

Procedural Management — Tympanostomy Tubes and Adenoidectomy

— Indications (AAO-HNS):

— Bilateral OME ≥3 months with documented hearing difficulty

— Unilateral or bilateral OME ≥3 months in at-risk children regardless of hearing

— OME of any duration with structural TM/middle ear damage

— Recurrent AOM with persistent effusion between episodes

— Not recommended for recurrent AOM without effusion between episodes

— Brief outpatient procedure under general anesthesia (mask, no IV typically)

— Myringotomy + insertion of grommet (short-term, ~12 months) or T-tube (long-term, 2+ years)

— Immediate hearing improvement; resolves effusion mechanically

— Water precautions: routine swimming in clean water generally permitted without plugs per AAO-HNS; plugs for diving, deep water, soapy bathwater

— Topical antibiotic drops (ofloxacin, ciprofloxacin/dexamethasone) for acute tube otorrhea — preferred over systemic antibiotics; avoid ototoxic aminoglycoside drops through a patent tube

— Follow-up audiometry to document hearing restoration

— Tubes typically extrude spontaneously in 6–18 months

— Add to tympanostomy when:

— Child is ≥4 years undergoing tube placement (reduces repeat surgery)

— Concurrent nasal obstruction, chronic adenoiditis, or chronic sinusitis

— Not recommended as primary procedure for OME alone in children <4 years unless distinct adenoid pathology

— ~20–30% of children require a second set after first extrusion

— Add adenoidectomy at second set if not already performed

— Otorrhea (10–25%), tympanosclerosis, persistent perforation (1–3% short-term tubes, higher with T-tubes), granulation, premature extrusion, retained tube

CCS pearl: When ordering ENT referral on CCS for chronic bilateral OME with hearing loss, advance the clock and re-examine after tube placement — expect resolved effusion, normalized tympanogram, and audiometric improvement. Document parental counseling on water precautions and otorrhea management.

Tympanostomy tubes (pressure equalization tubes) — primary surgical intervention:

Procedural details:

Postoperative care and counseling:

Adenoidectomy:

Repeat tube placement:

Complications:

Special Populations — Adults and Patients with Renal/Hepatic Disease

— Far less common than in children; almost always a sign of eustachian tube dysfunction from another process

— Unilateral persistent OME in an adult is nasopharyngeal carcinoma until proven otherwise

— Especially in patients of Southern Chinese, Southeast Asian, or North African descent (EBV-associated NPC)

— Associated features: epistaxis, nasal obstruction, cervical lymphadenopathy, cranial nerve deficits (CN III–VI)

— Mandatory flexible nasopharyngoscopy; biopsy any suspicious lesion; MRI with contrast

— Allergic rhinitis, chronic rhinosinusitis with nasal polyps

— Recent barotrauma (flight, diving)

— Radiation therapy to head and neck (post-treatment ETD)

— GERD/laryngopharyngeal reflux

— Smoking — strong association

— Treat underlying cause; intranasal corticosteroids reasonable if allergic/inflammatory

— Eustachian tube balloon dilation — emerging option for refractory adult ETD with OME

— Tympanostomy tubes performed in-office under local anesthesia

— Hearing aids if surgical management not pursued or contraindicated

— Minimal direct relevance; topical ototopical drops (fluoroquinolones) preferred over systemic agents — avoids dose adjustment

— Avoid aminoglycoside ototopical drops in patients with renal disease and TM perforation/tube — risk of systemic absorption and ototoxicity

— General anesthesia for tube placement requires hepatology coordination if advanced disease; topical management preferred

— Same NPC concern as younger adults, plus paraganglioma and other skull base lesions

— Sudden unilateral conductive loss warrants imaging

Key distinction: Pediatric OME is usually post-viral/post-AOM and self-limited. Adult OME, especially unilateral, demands a structural and oncologic workup. Do not transplant pediatric watchful-waiting logic onto adult patients.

Adult OME — fundamentally different workup:

Other adult etiologies:

Adult management:

Renal impairment considerations:

Hepatic impairment:

Older adults with new OME:

Special Populations — Cleft Palate, Down Syndrome, and At-Risk Pediatric Groups

— Near-universal OME due to abnormal tensor veli palatini function

— Standard recommendation: early tympanostomy tubes, often at the time of palate repair (~9–18 months)

— Do not apply standard 3-month watchful waiting

— Long-term audiology follow-up into school age; high rate of repeat tubes

— Screen for submucous cleft (bifid uvula, notched hard palate, zona pellucida) in unexplained recurrent OME

— Narrow ear canals, eustachian tube dysfunction, immune dysregulation → high OME prevalence

— Audiometry challenging — use age-appropriate or behavioral testing; ABR if needed

— Earlier ENT referral; tubes commonly required; consider longer-acting T-tubes given chronicity

— Coordinate with cardiology (AV canal defects), endocrinology (hypothyroidism affects hearing/speech), and developmental pediatrics

— High persistence of OME; multidisciplinary craniofacial team involvement

— Hearing preservation is critical for speech development

— At-risk designation — lower threshold for tubes

— Untreated hearing loss worsens language and social communication trajectory

— Sedation planning for audiometry and procedures

— Any additional conductive loss is disproportionately disabling

— Tubes considered earlier; coordinate with audiology, speech therapy, and special education

— Higher OME rates; coordinate with developmental follow-up clinic

— Adult women in pregnancy may develop transient ETD/OME from mucosal congestion

— Usually resolves postpartum; supportive care; avoid teratogenic decongestants (pseudoephedrine 1st trimester risk of gastroschisis association — limit use)

Step 3 management: For any at-risk child (cleft palate, Down syndrome, autism, developmental delay, blindness, permanent hearing loss), do not apply the 3-month watchful waiting window. Refer early to ENT and audiology — this is a recurring Step 3 distinction.

Cleft palate:

Down syndrome (trisomy 21):

Craniofacial syndromes (Pierre Robin, Treacher Collins, Apert, Crouzon):

Autism spectrum and developmental delay:

Children with permanent baseline hearing loss or blindness:

Prematurity:

Pregnancy:

Complications and Adverse Outcomes

— Conductive hearing loss averaging 25 dB; can reach 40 dB in some children

— Persistent bilateral loss during critical language acquisition window (6 months to 3 years) → speech and language delay, articulation errors, reduced expressive vocabulary

— Academic underachievement, attention difficulties, behavioral problems often attributed to other causes

— TM retraction pockets — chronic negative pressure draws TM medially

— Pars tensa or pars flaccida (attic) retraction — attic retraction strongly associated with cholesteatoma

— Atelectasis of the TM — collapse onto the promontory

— Adhesive otitis media — TM permanently adherent to middle ear structures

— Ossicular erosion — particularly long process of incus → conductive loss

— Tympanosclerosis — chalky white plaques in TM; usually cosmetic

— Cholesteatoma — keratinizing squamous epithelium in middle ear; erosive, potentially intracranial; surgical emergency

— Progression to AOM when bacterial superinfection occurs in retained fluid

— Rarely, mastoiditis or intracranial extension

— Otorrhea (most common, generally benign)

— Persistent perforation after tube extrusion (1–3% short-term, up to 15–20% T-tubes)

— Tympanosclerosis at insertion site

— Premature extrusion or retained tube

— Anesthesia-related risks (rare but real)

— Most children with brief OME episodes have no long-term developmental sequelae

— Persistent untreated bilateral OME during language acquisition is the highest-risk scenario

Board pearl: A white pearly mass in a retraction pocket or attic perforation with foul otorrhea is cholesteatoma — refer urgently to ENT. CT temporal bones is the imaging study. This is the most dangerous OME-related sequela because it erodes ossicles, mastoid, and can reach the dura.

Hearing-related complications:

Structural TM and middle ear complications:

Acute complications:

Post-tube complications:

Developmental and psychosocial outcomes:

When to Escalate Care — Specialist Referral and Inpatient Triage

— Bilateral OME ≥3 months

— Any duration in at-risk child

— Parental or clinician concern for hearing loss

— Failed school or newborn hearing screen with concurrent effusion

— Bilateral OME ≥3 months with documented hearing loss ≥21 dB better ear

— Unilateral OME persisting ≥6 months (Step 3 increasingly cites this lower threshold)

— At-risk child with persistent OME

— Structural concerns: retraction pocket, suspected cholesteatoma, ossicular erosion, recurrent perforation

— Recurrent AOM with effusion between episodes

— Adult with new OME, especially unilateral — urgent referral for nasopharyngoscopy

— Bilateral hearing loss ≥20 dB with effusion

— Any speech/language delay

— Atypical articulation or expressive language patterns

— Mastoiditis — postauricular swelling, protruding auricle, fever → IV antibiotics, CT, possible mastoidectomy

— Intracranial complications — meningitis, sigmoid sinus thrombosis, brain abscess → emergent neuroimaging and ID/neurosurgery

— Facial nerve palsy with middle ear pathology → urgent ENT and imaging

— Suspected cholesteatoma with complications — vertigo, sensorineural loss, CN findings

— Document audiometry before referral

— Communicate at-risk status and developmental concerns to ENT

— Ensure family understands surveillance vs surgical pathway

CCS pearl: On CCS, "refer to ENT" is appropriate when criteria are met; advance clock to outcome. For complications (mastoiditis), order IV ceftriaxone, CT temporal bones, ENT consult, admit simultaneously — do not waste virtual time on sequential ordering.

OME is fundamentally outpatient — admission is rare and reserved for complications

Referral to audiology:

Referral to otolaryngology (ENT):

Speech-language pathology referral:

Inpatient/ED escalation triggers (uncommon but high-stakes):

Care coordination:

Key Differentials — Other Otologic Causes of Hearing Loss/Ear Symptoms

— Acute onset otalgia, fever, irritability, bulging erythematous TM, decreased mobility

— Treatment: amoxicillin 80–90 mg/kg/day first line; alternatives if penicillin allergy or treatment failure

— Distinguished from OME by acute inflammatory signs, not just fluid

— Persistent TM perforation with chronic otorrhea ≥6 weeks

— Topical fluoroquinolone drops; ENT referral

— Can complicate prior AOM or retained tubes

— Keratin debris in middle ear/mastoid

— Foul-smelling otorrhea, conductive loss, attic retraction pocket, white pearly mass

— Surgical management — tympanomastoidectomy

— Traumatic (Q-tip, slap, barotrauma) or post-AOM

— Conductive loss; most heal spontaneously in 4–6 weeks

— Keep ear dry; ENT if persistent >3 months

— Common confounder; can cause conductive loss and abnormal otoscopy

— Remove (irrigation, curette, ceruminolytic) and re-examine TM

— Young to middle-aged adult, progressive conductive loss, Carhart notch at 2 kHz, family history

— Normal TM appearance; tympanometry shows As pattern (shallow peak)

— Stapedectomy or hearing aid

— Bone conduction also reduced; Rinne reversed pattern absent

— Audiometry distinguishes; etiologies include congenital, noise, ototoxicity, presbycusis

— Aural fullness, popping; Type C tympanogram; no fluid

— Self-limited; treat allergic/inflammatory triggers

Key distinction: AOM = pain + bulging + acute. OME = fluid + no acute symptoms. CSOM = perforation + chronic drainage. Cholesteatoma = retraction pocket + keratin mass + foul drainage. These four diagnoses are the highest-yield otologic differential cluster on Step 3.

Acute otitis media (AOM):

Chronic suppurative otitis media (CSOM):

Cholesteatoma:

Tympanic membrane perforation:

Cerumen impaction:

Otosclerosis:

Sensorineural hearing loss:

Eustachian tube dysfunction without effusion:

Key Differentials — Non-Otologic Mimics and Systemic Causes

— Adult or adolescent with persistent unilateral OME

— EBV-associated; Southern Chinese, Southeast Asian, North African descent

— Other clues: epistaxis, neck mass (often first sign), cranial nerve palsies (CN VI most common)

— Flexible nasopharyngoscopy + biopsy + MRI with contrast

— Mouth breathing, hyponasal speech, snoring, OSA features

— May contribute to OME via mechanical obstruction and bacterial reservoir

— Adenoidectomy when persistent symptoms or recurrent OME with tube failure

— Sneezing, clear rhinorrhea, allergic shiners, transverse nasal crease, cobblestoning

— Contributes to ETD; treat on its own merits with intranasal corticosteroids and second-generation antihistamines

— ≥12 weeks of nasal obstruction, facial pressure, purulent discharge, hyposmia

— Imaging if refractory; ENT for surgical evaluation

— Posterior laryngeal erythema; associated with chronic ETD in adults and some children

— Lifestyle measures; PPI trial only if reflux independently established

— Autophony (hearing own voice/breathing), aural fullness; symptoms improve when supine

— Often seen with weight loss, pregnancy; usually benign

— Global developmental delay, autism spectrum, primary language disorder, intellectual disability

— Hearing must always be evaluated first when speech delay is identified

— Asymmetric sensorineural loss with tinnitus, vestibular symptoms; MRI internal auditory canal

— Not OME but on the differential for adult ear complaints

— Always rule out hearing impairment before attributing inattention to behavioral or attentional diagnoses

Board pearl: A child being evaluated for "possible ADHD" or speech delay should have hearing tested first. A normal audiogram is required before pursuing behavioral or developmental diagnoses. Step 3 stems hide OME-related hearing loss inside attention or learning complaints.

Nasopharyngeal carcinoma (NPC):

Adenoid hypertrophy:

Allergic rhinitis:

Chronic rhinosinusitis:

GERD/laryngopharyngeal reflux:

Patulous eustachian tube:

Speech delay from other causes:

Acoustic neuroma (in adults):

Inattention/ADHD vs hearing loss:

Secondary Prevention, Risk Reduction, and Long-Term Plan

— Tobacco smoke exposure elimination — strongest modifiable factor; both prenatal and postnatal

— Counsel all caregivers; offer cessation resources, varenicline/bupropion/NRT to adult smokers

— Breastfeeding — encourage exclusively for first 6 months; protective against AOM and OME

— Avoid bottle propping and supine feeding

— Limit pacifier use after 12 months

— Daycare considerations — smaller group sizes if feasible

— Pneumococcal conjugate vaccine (PCV15 or PCV20) per current ACIP schedule — reduces AOM and indirectly OME

— Annual influenza vaccine ≥6 months of age — reduces AOM following influenza

— Routine childhood immunizations up to date

— Treat allergic rhinitis when present (intranasal corticosteroids, second-generation antihistamines)

— Address GERD when independently diagnosed

— Audiometry after tube placement to document hearing restoration

— Surveillance for tube otorrhea, premature extrusion, retained tube

— Plan for possible second set if recurrence after extrusion

— Adenoidectomy at second tube placement if not previously performed

— Quarterly assessments; coordinated with developmental pediatrics, speech-language pathology, audiology

— Hearing-preserving interventions prioritized

— Early intervention services (Part C, age <3) or school-based services (Part B, age ≥3) per IDEA

— Speech therapy when delays identified

— Recognize signs of hearing difficulty

— Understand that OME is typically self-limited and antibiotics are not indicated

— Know when to seek re-evaluation (worsening hearing, ear pain, drainage)

Step 3 management: Tobacco smoke elimination + breastfeeding promotion + pneumococcal/influenza vaccination are the three evidence-based preventive interventions. These appear as the "best preventive measure" answer in Step 3 stems involving recurrent AOM/OME.

Modifiable risk factors — counsel aggressively:

Vaccination optimization:

Allergy and reflux management:

Post-tube long-term plan:

At-risk children — longitudinal care:

Speech and language support:

Family education:

Follow-Up, Monitoring Parameters, and Counseling Cadence

— Initial diagnosis → reassess at 3 months with pneumatic otoscopy ± tympanometry

— If persistent at 3 months → audiometry

— Continue surveillance every 3–6 months until resolution, hearing loss, or structural change prompts intervention

— Document onset date and duration at every visit

— Reassess every 3 months; do not extend to 6

— Earlier audiology and ENT involvement

— 2–4 weeks post-op: ENT visit, otoscopy, document tube position

— Audiometry within several weeks to confirm hearing restoration

— Every 6 months until tube extrusion

— After extrusion: confirm TM healing and document hearing

— TM appearance, mobility (pneumatic otoscopy)

— Tympanometry — Type A confirms resolution

— Audiometry — return to age-appropriate thresholds

— Speech-language milestones at each well-child visit

— School performance and teacher reports

— Reinforce smoke-free environment

— Reinforce hand hygiene during URI seasons

— Update vaccination status

— Discuss signs of worsening: persistent hearing difficulty, ear pain, fever, drainage, balance changes

— For tube patients: water precautions per AAO-HNS (routine swimming usually permitted; plugs for diving/soapy water)

— Audiometric reports for IEP/504 plans

— Communicate with school nurse for FM systems, preferential seating

— Hand-off between PCP and ENT requires shared documentation of duration, audiometry, at-risk status

— Communicate post-tube care plan to PCP for interval visits

CCS pearl: On CCS, after referring for tubes, advance clock 2–4 weeks: order otoscopy, tympanometry, audiometry to confirm resolution. Document parent counseling and schedule the next surveillance visit. Closing the loop is part of the case credit.

Standard surveillance schedule (non-at-risk child):

At-risk child cadence:

Post-tube follow-up (CCS-style):

Monitoring parameters:

Counseling content at every visit:

Documentation for school and early intervention:

Transition of care:

Ethical, Legal, and Patient Safety Considerations

— Discuss benefits (immediate hearing improvement, reduced AOM recurrence) and risks (otorrhea, tympanosclerosis, persistent perforation, anesthesia)

— Discuss alternatives: continued watchful waiting, hearing aids, autoinflation

— Document parental/guardian consent; assent from older children

— Shared decision-making is the standard, particularly when criteria are borderline

— Prescribing antibiotics for OME contributes to resistance, C. difficile, allergic reactions, and microbiome disruption

— Documented refusal to prescribe inappropriate antibiotics, with parent education, is a patient safety act

— Failing to identify and act on persistent bilateral OME with hearing loss in at-risk children risks preventable speech/language delay — a foreseeable harm

— Step 3 frequently tests recognition of the at-risk designation

— PCP-to-ENT handoff: communicate audiometry, duration, at-risk status, prior management

— Post-tube handoff: ensure PCP knows water precautions, signs of otorrhea, follow-up schedule

— Failure to follow up on hearing concerns is a documented source of pediatric malpractice claims

— Children with hearing loss qualify for accommodations under IDEA; failure to refer is an equity issue

— Provide audiometric documentation to school

— Unexplained TM perforation or hemotympanum in a child without consistent history → consider non-accidental trauma; report per state law

— Cigarette smoke exposure is a health concern but not generally reportable

— Use professional interpreters for parental counseling; avoid family/child interpreters

— Address health literacy regarding the natural history of OME and reasons not to prescribe antibiotics

— Eustachian tube balloon dilation in adults — discuss evidence and coverage

— Avoid recommending unproven therapies (homeopathy, chiropractic adjustment)

Board pearl: A child with persistent unilateral hemotympanum or multiple TM perforations without a coherent explanation requires evaluation for non-accidental trauma. Pediatricians are mandated reporters; documentation and CPS referral are required even when uncertainty exists.

Informed consent for tympanostomy tubes:

Avoiding overtreatment — antibiotic stewardship:

Avoiding undertreatment — developmental harm:

Transitions of care:

School and early intervention coordination:

Mandatory reporting considerations:

Cultural and language considerations:

Off-label and emerging therapies:

High-Yield Associations and Rapid-Fire Clinical Facts

Key distinction: OME and AOM share the finding of middle ear fluid, but only AOM has acute inflammation. The Step 3 distractor is to treat any fluid with antibiotics — recognize the absence of acute signs to land on OME.

The 3-month rule: bilateral OME ≥3 months with hearing loss → ENT referral for tubes

Type B tympanogram + normal canal volume = effusion (classic OME)

Type B tympanogram + large canal volume = patent tube or perforation

Type C tympanogram = negative middle ear pressure / ETD

Type A tympanogram = normal — excludes effusion

Pneumatic otoscopy is the gold standard exam — required AAO-HNS recommendation

At-risk children: cleft palate, Down syndrome, autism, developmental delay, blindness, permanent hearing loss, syndromic craniofacial — refer early

Adult unilateral OME = NPC until proven otherwise → nasopharyngoscopy

Average conductive loss in OME: ~25 dB; up to 40 dB

No role for: antibiotics, antihistamines, decongestants, systemic steroids in routine OME

Strongest modifiable risk factor: tobacco smoke exposure

Vaccines that reduce OME burden: pneumococcal conjugate, annual influenza

Cleft palate: near-universal OME → tubes typically at palate repair

Down syndrome: narrow canals + ETD + immune issues → early tubes, longer-acting T-tubes considered

Cholesteatoma signs: attic retraction pocket, foul otorrhea, white pearly mass → ENT urgent

Tube otorrhea treatment: topical fluoroquinolone drops (ofloxacin, cipro/dex); avoid aminoglycosides through patent tube

Tubes and swimming: routine swimming OK; ear plugs for diving, soapy bathwater

Adenoidectomy with tubes: add if child ≥4 years or at second tube set

Submucous cleft: bifid uvula, notched hard palate, zona pellucida — consider in recurrent OME

Carhart notch at 2 kHz = otosclerosis (a differential, not OME)

Speech delay workup: test hearing first

Eustachian tube anatomy: more horizontal in children → poor drainage → higher OME risk

Most common bacteria in coexisting AOM: S. pneumoniae, nontypeable H. influenzae, M. catarrhalis

Board Question Stem Patterns

— "A 3-year-old completed amoxicillin 4 weeks ago for AOM. Asymptomatic. Exam: dull immobile TM bilaterally, no erythema."

— Answer: Reassurance and reassessment in 3 months (watchful waiting); not antibiotics, not steroids

— "A 4-year-old with 4 months of bilateral effusion. Audiometry shows 30 dB conductive loss bilaterally."

— Answer: Refer to ENT for tympanostomy tubes

— "A 2.5-year-old with limited expressive vocabulary, parents wonder if hearing is affected."

— Next step: Audiometry / formal hearing evaluation before any developmental workup

— "An 18-month-old with Down syndrome has bilateral OME for 6 weeks."

— Answer: Audiology and ENT referral now — do not wait 3 months

— "A 45-year-old man of Southern Chinese descent presents with 2 months of left ear fullness; left Type B tympanogram, right normal."

— Answer: Flexible nasopharyngoscopy — rule out NPC

— Multiple-choice: amoxicillin / pseudoephedrine / oral prednisone / refer for audiology

— Answer: Audiology referral — pills don't treat OME

— "A 5-year-old with tubes develops painless ear drainage after swimming."

— Answer: Topical ofloxacin drops, not oral antibiotics, not aminoglycoside drops

— "Chronic foul-smelling otorrhea, attic retraction pocket with white mass."

— Answer: ENT referral for tympanomastoidectomy, CT temporal bones

— Flat tracing + normal canal volume → effusion

— Flat tracing + large canal volume → perforation/patent tube

— Recurrent AOM/OME, best modifiable intervention → Eliminate tobacco smoke exposure

Step 3 management: Read for duration, laterality, hearing status, and at-risk designation in every OME stem. These four variables select among watchful waiting, audiology referral, ENT referral, or urgent workup. Distractor answers will always include antibiotics — anchor on the AAO-HNS framework.

Pattern 1 — Post-AOM follow-up:

Pattern 2 — Persistent bilateral OME with hearing loss:

Pattern 3 — Speech delay vignette:

Pattern 4 — At-risk child:

Pattern 5 — Adult unilateral OME:

Pattern 6 — Pharmacology trap:

Pattern 7 — Tube otorrhea:

Pattern 8 — Cholesteatoma flag:

Pattern 9 — Tympanogram interpretation:

Pattern 10 — Prevention question:

One-Line Recap

Otitis media with effusion is middle ear fluid without acute inflammation that resolves spontaneously in most children, requires neither antibiotics nor decongestants, and demands audiology plus ENT referral for tympanostomy tubes when bilateral effusion persists ≥3 months with documented hearing loss or when the child is at developmental risk.

Board pearl: The four variables that drive every Step 3 OME answer are duration, laterality, hearing loss, and at-risk status — read for these in the stem, apply the 3-month rule, refuse the antibiotic distractor, and the question solves itself.

Diagnose by pneumatic otoscopy (dull, immobile, retracted TM without erythema or bulging) confirmed by tympanometry (Type B with normal canal volume = effusion)

Manage by watchful waiting with 3-month reassessments; aggressively avoid antibiotics, antihistamines, decongestants, and systemic steroids — none are recommended; offer tobacco smoke elimination, breastfeeding, and pneumococcal/influenza vaccination as evidence-based prevention

Refer to audiology for bilateral OME ≥3 months or any hearing concern; refer to ENT for tubes when bilateral OME ≥3 months coexists with hearing loss ≥21 dB, when the child is at-risk (cleft palate, Down syndrome, autism, developmental delay, blindness, permanent hearing loss), or when structural damage (retraction pocket, cholesteatoma) is suspected

Escalate urgently for adult unilateral OME (nasopharyngeal carcinoma until proven otherwise → nasopharyngoscopy), cholesteatoma signs (attic retraction with foul otorrhea and pearly mass), mastoiditis, or intracranial complications; treat tube otorrhea with topical fluoroquinolone drops while avoiding ototoxic aminoglycosides through a patent tube